Day: January 22, 2024

Issues Open Letter to Shareholders NEW YORK, Jan. 22, 2024 (GLOBE NEWSWIRE) — Genco Shipping & Trading Limited (NYSE:GNK) (“Genco” or the “Company”), the largest U.S. headquartered drybulk shipowner focused on the global transportation of commodities, today issued a letter to shareholders highlighting steps the Company is continuing to take to drive sustainable, long-term shareholder value. The full text of the letter follows: Dear Fellow Shareholders, We are writing today with an update on the important steps we continue to take at Genco to drive sustainable, long-term shareholder value for you. Over the last several years, our Board of Directors and management team have navigated various market environments, exhibited a disciplined approach to capital allocation and overseen the successful transformation of the Company while...

Temecula, CA , Jan. 22, 2024 (GLOBE NEWSWIRE) — Global Warming Solutions, Inc. (OTCQB: GWSO), a pioneer in developing advanced technologies that combat climate change, is excited to announce the appointment of Dr. Jason McKenna to its Advisory Board. This strategic addition underlines our commitment to leading the charge against global climate challenges through innovative solutions. Dr. McKenna, a distinguished figure with over 25 years of experience in national security R&D, hydrocarbon exploration, and renewable energy technologies, including hydrogen production and storage, brings a wealth of knowledge to GWSO. Dr. McKenna is poised to make significant contributions to our mission with his Ph.D. in Geophysics from Southern Methodist University and his role as Director of RDTE&T at the University of Southern Mississippi’s...

Positive Phase 2b data announced for BNC210 on reduction of total symptom severity and multiple symptom clusters in post-traumatic stress disorder (PTSD), with a discussion with the U.S. Food & Drug Administration (FDA) anticipated in Q2’24. Positive End of Phase 2b (EoP2) meeting with FDA announced for BNC210 in Social Anxiety Disorder (SAD) following the Phase 3-enabling PREVAIL Phase 2 trial data readout. The Company is actively engaged in strategic partnership discussions with interested parties for multiple pipeline assets and is evaluating options to proceed with clinical development plans for BNC210 in both PTSD and SAD. ADELAIDE, Australia and CAMBRIDGE, Mass., Jan. 22, 2024 (GLOBE NEWSWIRE) — Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class,...

Table 1.Summary table for historical drill holes Bz6, Bz16 and Bz20 from the Berezski East Target, Elemes ProjectFigure 1.Arras Minerals License Package (Pavlodar, Kazakhstan)Figure 2.Location of the three holes re-assayed by Arras at the Berezski East project, Elemes Project. Collars for all historical drilling are shown.Figure 3.The Location of the Berezski East target in relation to the Quartzite Gorka and Karagandy-Ozek targets previously announced by Arras Minerals. Intense alteration and widespread surface mineralization across a 5-kilometer strike is indicating a big, largely untested porphyry system in the Elemes Licence area.VANCOUVER, British Columbia, Jan. 22, 2024 (GLOBE NEWSWIRE) — Arras Minerals Corp. (TSX-V: ARK) (“Arras” or “the Company”) is pleased to announce the results from...

Figure 1Stallion Uranium’s Eastern Basin ProjectsVANCOUVER, British Columbia, Jan. 22, 2024 (GLOBE NEWSWIRE) — Stallion Uranium Corp. (the “Company” or “Stallion”) (TSX-V: STUD; OTCQB: STLNF; FSE: HM40) is pleased to announce that the Company has entered into a non-binding letter of intent (the “LOI”), under which the Company has granted an unnamed party (the “Optionor”) the option to acquire a 100% interest in its Eastern Basin Projects, comprising seven (7) mineral claims totalling approximately 10,874 hectares (25,870 acres) and located in the Province of Saskatchewan (the “Property”). “The sale of Stallion’s eastern Athabasca Basin projects allow the Company to focus on our core projects in the Western Athabasca Basin while seeing these projects advanced,” commented Drew Zimmerman, CEO. “We...

MELBOURNE, Australia, Jan. 22, 2024 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces presentations featuring the Company’s theranostic programs at the upcoming American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2024) to be held in San Francisco, CA (US) from 25 – 27 January 2024. Dr David N. Cade, Telix Group Chief Medical Officer, said, “We are pleased to present updates on our late-stage therapeutic programs for prostate and kidney cancer at ASCO GU 2024, the leading specialised event for GU cancer care worldwide. “The ProstACT GLOBAL study of TLX591 (177Lu rosopatamab tetraxetan) will be presented, the first Phase III trial to evaluate TLX591, our lead radio-antibody drug conjugate (rADC) therapy candidate in patients with PSMA-positive metastatic castrate-resistant...

DALLAS, Jan. 22, 2024 (GLOBE NEWSWIRE) — Right on Brands, Inc. (OTC PINK: RTON), a fully reporting SEC company and a leading developer of a diverse range of hemp-based and THCA products, announced today the withdrawal of its REG A offering effective January 16, 2024. The decision reflects the company’s pledge to its shareholders, believing that its improved financial position negates the need to sell shares at current market prices. Market conditions and the company’s growth prospects are showing rapid signs of improvement, and Right on Brands is optimistic about its future trajectory. With eight established stores and a portfolio consisting of over 100 SKU’s, the company is confident in its potential for explosive growth throughout 2024. “Our decision to let the REG A offering expire is a strategic move in line with our rock-solid...

SINGAPORE and SHANGHAI, China, Jan. 22, 2024 (GLOBE NEWSWIRE) — H World Group Limited (NASDAQ: HTHT and HKEX: 1179) (“H World”, “we” or “our”), a key player in the global hotel industry, today announced preliminary results for hotel operations in the fourth quarter (“Q4 2023”) and the full year ended December 31, 2023. Business update For our Legacy-Huazhu business, our RevPAR in Q4 2023 recovered to 120% of the 2019 level, supported by the sustained recovery in both leisure and business travel demand. Breaking down into each month, our RevPAR in October, November and December 2023 recovered to 120%, 117% and 123% of the 2019 levels, respectively. For the full year of 2023, our RevPAR reached 122% of the 2019 level. While the RevPAR growth in 2023 was primarily driven by ADR, we also experienced continuous recovery in the occupancy...

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND POSSESSIONS), AUSTRALIA, JAPAN, CANADA, HONG KONG, NEW ZEALAND, SINGAPORE OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE IN ACCORDANCE WITH APPLICABLE LAW. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE SECTION “IMPORTANT INFORMATION” AT THE END OF THE PRESS RELEASE. Fingerprint Cards AB’s (publ) (“Fingerprints” or the “Company”) announced on 16 January 2024 that the Company will pay the second amortisation and interest payment under its outstanding convertible bonds (the “Convertible Bonds”) with new B-shares. Following calculations under the terms and conditions of the Convertible Bonds,...